vipadenant
Busy week at Juno Therapeutics ends with takeover of RedoxTherapies
July 15, 2016Medical Communications, Research and Development, Sales and Marketing juno therapeutics, redoxtherapies, takeover, vipadenant
Juno Therapeutics (NASDAQ: JUNO) has announced the acquisition of RedoxTherapies, adding its lead cancer drug candidate, vipadenant, to its portfolio.
Latest content
Highlighting the value of lab research for healthcare innovation
November 2, 2026
Medtronic secures CE Mark for new cardiac pacing portfolio
October 30, 2026
Dermatology leader Doncker is new Onicor CEO
October 29, 2026
